CClinicalTrials.gg
CompletedNCT03406637Updated Mar 6, 2020

Combined Prospective and Retrospective Post-Market Follow Up of the 'BPK-S Integration' UC as Primary Implant in the Variant CoCr

An observational study in Osteoarthritis, Knee and Joint Instability, sponsored by Peter Brehm GmbH. Completed at 2 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-06.

Sponsored by Peter Brehm GmbH · Observational

Study type
Observational
Model
Case-only
Time perspective
Other
Enrollment
62
Ages
18 Years and older
Sex
All
01

Study summary

Patients who received a total knee endoprosthesis BPK-S Integration between 2011 and 2013 will be invited to participate in this PMCF study provided sufficient source data documentation is available regarding preoperative, intraoperative and early postoperative follow-up assessments.

Only patients providing written informed consent prior to any study data collection can take part in the study.

Preoperative, intraoperative and early postoperative data (3 months, 1 year and 2 years after implantation) will be collected retrospectively. Additional long-term follow-up of one visit (year 7 after implantation) will be documented prospectively.

Only parameters assessed in clinical standard care for follow-up (implant control) visits will be collected for this PMCF study.

Radiological assessment of the implanted prosthesis will only be conducted if medically indicated according to the investigator. No additional study related assessment will be performed.

Only anonymized data will be used in this observational study to protect patient privacy. No personally identifiable information will be collected.

02

Conditions studied

  • Osteoarthritis, Knee
  • Joint Instability
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients that received a BPK-S Integration in the variant CoCr as primary total knee endoprosthesis between 2011 and 2013 implanted by the investigator

Inclusion criteria

  • Patients that received a total primary knee endoprosthesis BPK-S Integration (Co28Cr6Mo) between 2011 and 2013
  • Patients that agree to participate and give written informed consent to the anonymized retrospective and prospective data collection within the study

Exclusion criteria

Exclusion Criteria:

No study specific exclusion criteria are defined for this PMCF study.

04

Study design

Observational model
Case-only
Time perspective
Other
Enrollment
62 participants (actual)
Patient registry
No

Interventions

  • DeviceBPK-S Integration

    primary total knee endoprosthesis

05

What researchers measure

Primary outcomes

  1. Patient relevant benefit after 5 years

    improvement of KSS-Score by at least one category as compared to preoperative basic assessment

    Time frame: 7 years

Secondary outcomes

  1. Safety parameters

    Incidents that require reporting to the competent authority and complications during and after surgery as documented in source documentation

    Time frame: 7 years

  2. Patient relevant benefit as measured by American Knee Society Score

    improvement of KSS-Score as compared to preoperative basic assessment

    Time frame: 1 year

  3. Implant Loosening Number

    Number of implant loosening due to quality issues with the implant

    Time frame: 7 years

  4. Implant Loosening Reason

    Reason for implant loosening due to quality issues with the implant

    Time frame: 7 years

  5. Revision Number

    Number of revisions, if required

    Time frame: 7 years

  6. Revision Reason

    Reason for revision, if required

    Time frame: 7 years

  7. Surgery Parameters

    Evaluation of surgery time as documented in the surgical report

    Time frame: Day 0 = day of surgery

  8. Surgery Parameters

    Evaluation of tourniquet time as documented in the surgical report

    Time frame: Day 0 = day of surgery

06

Study locations

2 sites
  • Centre Hospitalier de Wallonie picarde - CHwapi A.S.B.L
    Tournai, 7500, Belgium
  • Medical Center Tournai
    Tournai, 7500, Belgium
07

Registry details

Key details

Study ID
NCT03406637
Lead sponsor
Peter Brehm GmbH
Collaborators
P.R.I.S.M.A.-CRO
Responsible party
Sponsor
First posted
Jan 23, 2018
Start date
Oct 17, 2018
Primary completion
Mar 2, 2020
Completion
Mar 2, 2020
Last update
Mar 6, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion